Substance / Medication

Azithromycin

Overview

Active Ingredient
azithromycin
RxNorm CUI
18631

Indications

Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.

Labeler: Dispensing Solutions, Inc.Updated: 2011-10-03T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Azithromycin is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

90 trials linked to this intervention

90
Total Trials
17
Recruiting
27
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Azithromycin in Infants With Bronchiolitis: A Systematic Review and Meta-Analysis.
Loveys Kate, Haskell Libby, Cotterell Elizabeth et al. · Acta Paediatr · 2026
PMID: 41074495Meta-Analysis
Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis.
Joseph Meghna, Murali Krishna Mrinal, Karlinksi Vizentin Vanessa et al. · Neonatology · 2025
PMID: 40795809Meta-Analysis
Significant Predictors of Azithromycin in Population Pharmacokinetic Analysis: A Systematic Review.
Zhang Runcong, Fang Yuebin, Wang Yinhui et al. · Drug Des Devel Ther · 2025
PMID: 40636323Meta-AnalysisFull text (PMC)
Biannual azithromycin mass drug administration for reduction of childhood mortality: a systematic review and meta-analysis.
Gurunthalingam Meenalotchini Prakash, Singh Madhusudan Prasad, Gaikwad Nitin Rewaram · J Antimicrob Chemother · 2025
PMID: 40129224Meta-Analysis
Influential predictors of azithromycin pharmacokinetics: a systematic review of population pharmacokinetics.
Methaneethorn Janthima, Jiao Zheng, AlEjielat Rowan et al. · Ann Med · 2025
PMID: 40372973Meta-AnalysisFull text (PMC)
Examining the safety and efficacy of Azithromycin in Cystic fibrosis: A systematic review and Meta-analysis.
Elmegeed Aya Abd, Lotfy Mariam A, Abdullah Ahmed R et al. · J Infect Chemother · 2025
PMID: 40554009Meta-Analysis
Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials.
Lau Chuen-Yen, Qureshi Azhar K · Sex Transm Dis · 2002
PMID: 12218839Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Azithromycin (substance)
SNOMED CT
387531004
UMLS CUI
C0052796
RxNorm CUI
18631
Labeler
Dispensing Solutions, Inc.

Clinical Data

This intervention maps to 14 entities in the Healos knowledge graph.

14
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
90
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.